Novo Nordisk (NVO) and Eli Lilly (LLY) shares dip in reaction to a Harvard study that found GLP-1 weight-loss drugs Ozempic and Wegovy could be linked to rare cases of vision loss.

Yahoo Finance health reporter Anjalee Khemlani explains the study's findings.

For more expert insight and the latest market action, click here to watch this full episode of Market Domination.

This post was written by Luke Carberry Mogan.